Condition: Geographic Atrophy Due to Age-Related Macular Degeneration · Sponsor: Theratocular Biotek Co.
This study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of TO-O-1007, a biodegradable sustained-release intravitreal implant, for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). A long-acting intravitreal implant providing sustained delivery of API over 6 months may slow the progression of GA lesions while reducing treatment burden associated with frequent intravitreal injections. TO-O-1007 may offer a convenient treatment option with the potential to preserve retinal structure and visual function while maintaining an acceptable safety profile.
This description comes directly from the study's public registry record.
Weian Chien · +886 (2) 2790-6566 · weian@metagone.com.tw
Chung-Hsin Tsai · +886 (2) 2790-6566 · brian@metagone.com.tw
Always discuss trial participation with your own doctor first.
| Retina & Eye Consultants | Hurstville, New South Wales (nsw), Australia | Recruiting |
| Sydney Retina Clinic & Day Surgery | Sydney, New South Wales (nsw), Australia | Recruiting |
| Launceston Eye Doctors | Launceston, Tasmania (tas), Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07668804